FMA
NKTR icon

FNY Managed Accounts’s Nektar Therapeutics NKTR Stock Holding History

FNY Managed Accounts’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$2K Sell
2
-2
-50% -$2.58K ﹤0.01% 409
2017
Q4 		$3K Buy
+4
New +$2.37K ﹤0.01% 432

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FNY Managed Accounts's NKTR Position: Q1 2018 in Review

FNY Managed Accounts reduced its Nektar Therapeutics (NKTR) stake by 50% in Q1 2018, selling an estimated $2.58K and leaving 2 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #409.

FNY Managed Accounts first reported a position in NKTR in Q4 2017 and has held it in 2 quarters since. The position peaked at $3K in Q4 2017. 359 funds tracked by Wall St. Rank hold NKTR as of Q1 2018.

  • FNY Managed Accounts held 2 shares of Nektar Therapeutics worth $2K as of Q1 2018.
  • FNY Managed Accounts sold 2 Nektar Therapeutics shares in Q1 2018, an estimated $2.58K.
  • Nektar Therapeutics made up ﹤0.01% of FNY Managed Accounts's portfolio in Q1 2018, its #409 holding.
  • FNY Managed Accounts first reported a position in Nektar Therapeutics in Q4 2017 and has held it in 2 quarters since.
  • FNY Managed Accounts's Nektar Therapeutics position peaked at $3K in Q4 2017.
  • 359 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.